Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma

Journal of Clinical Oncology

Volumn 10, Issue 5, 1992, Pages 790-794

  Redman, John R ^a,b,c   Cabanillas, Fernando ^a   Velasquez, William S ^a   McLaughlin, Peter ^a   Hagemeister, Fredrick B ^a   Swan Jr , Forrest ^a   Rodriguez, Maria A ^a   Plunkett, William K ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b WYETH AYERST RESEARCH   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; AGED; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMAN; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 0026777233     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1992.10.5.790     Document Type: Article

References (28)

1. Bodey GP, Gottlieb J, McCredie KB, et al: Adenine arabinoside in cancer chemotherapy, in Pavan-Langston D, Buchanan RA, Alford CA Jr (eds): Adenine Arabinoside: An Antiviral Agent. New York, NY, Raven, 1975, pp 281-285
2. Brockman RW, Cheng Y-C, Schabel FM Jr, et al: Metabolism and chemotherapeutic activity of 9-β-D-arabino-furanosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 40:3610-3615, 1980
3. Brockman RW, Schabel RM Jr, Montgomery JA: Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyl adenine. Biochem Pharmacol 26:2193-2196, 1977
4. Hutton JJ, Von Hoff DD, Kuhn J, et al: Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 44:4183-4186, 1984
5. Kavanagh JJ, Krakoff IH, Bodey GP: Phase I study of fludarabine (2-fluoro-ara-AMP). Eur J Cancer Clin Oncol 21:1009-1011, 1985
6. Casper ES, Mittelman A, Kelson D, et al: Phase I clinical trial of fiudarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15:233-235, 1985
7. Warrell RP, Berman E: Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol 4:74-79, 1986
8. Leiby JA, Snider KM, Kraut EH, et al: Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47:2719-2722, 1987
9. Hochster H, Kim K, Green M, et al: Fludarabine is highly active in refractory low grade lymphoma. Proc Am Soc Clin Oncol 8:254, 1989 (abstr)
10. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia Blood 74:19-26, 1989
11. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine-Results of therapy in previously treated (PT) and untreated (UNT) chronic lymphocytic leukemia (CLL). Blood 72:207a, 1988 (abstr; suppl 1)
12. Kraut EH, Grever MR, Salmon S: Phase II trial of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group (SWOG) study. Proc Am Assoc Cancer Res 30:264, 1989 (abstr)
13. Weiss GR, Crowley J, Von Hoff DD, et al: Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. Cancer Treat Rep 70:1123-1124, 1986
14. Kavanagh JJ, Stringer CA, Copeland LJ, et al: Phase II trial of fludarabine in patients with epithelial ovarian cancer. Cancer Treat Rep 70:425-426, 1986
15. Pazdur R, Samson MK, Baker LH: Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas. Am J Clin Oncol 10:341-343, 1987
16. Carpenter JT Jr, Vogel CL, Wang G, et al: Phase II evaluation of fludarabine in patients with metastatic breast cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1235-1236, 1986
17. Cascino TL, Brown LD, Morton RF, et al: Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11:586-588, 1988
18. Kish JA, Von Hoff D, Samson M, et al: Evaluation of fludarabine phosphate NSC (312887) in malignant melanoma. A phase II SWOG study. Proc Am Assoc Cancer Res 30:1091, 1989 (abstr)
19. Ashenhurst J, Kilton L, Greenburg A, et al: Phase II trial of fludarabine phosphate (FAMP) in metastic gastric adenocarcinoma: An Illinois Cancer Council study. Proc Am Soc Clin Oncol 8:114, 1989 (abstr)
20. Warrell RP, Coonley CJ, Straus DJ, et al: Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer 51:1982-1987, 1983
21. Radice PA, Bunn PA, Ihde DC: Therapeutic trials with VP-16-213 and VM-26: Active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep 63:1231-1239, 1979
22. Warrell RP, Lee BJ, Kempin SJ, et al: Effectiveness of methyl GAG (methylglyoxyl bis-guanylhydrazone) in patients with advanced malignant lymphoma. Blood 57:1011-1014, 1981
23. Kantarjian H, Barlogie B, Plunkett W, et al: High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1:689-694, 1983
24. Case DC, Hayes DM: Phase II study of aziridinylbenzoquinone in refractory lymphoma. Cancer Treat Rep 67:993-996, 1983
25. Gams RA, Steinberg J, Posner L: Mitoxantrone in malignant lymphoma. Semin Oncol 11:47-49, 1984 (suppl 1)
26. Gilewski TA, Richards JM: Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 17:74-87, 1990
27. Chun HG, Leyland-Jones BR, Caryk SM, et al: Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225-1288, 1986
28. Adjei AA, Dagino I, Wong M, et al: Protection of L1210 bearing mice against the neurotoxicity of fludarabine by nitrobenzylthioinosine (NBMPR). Proc Am Assoc Cancer Res 30:494, 1989 (abstr)